SALT LAKE CITY, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will provide ...
Earnings call Recursion delivered a strong Q3 2025, ending with $785 million in cash (as of October 9), providing runway through 2027 without additional financing. Management reaffirmed expense ...
Recursion Pharmaceuticals Inc. (RXRX) reported its third-quarter 2025 earnings, revealing a mixed performance with an EPS of -$0.36, slightly surpassing the forecast of -$0.37. However, the company ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The recent earnings call for Recursion ...
Recursion narrowly beat EPS expectations, signaling effective cost management. Revenue fell short by 69.44%, raising concerns about growth prospects. The company maintains a strong cash position with ...
Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an optimistic sentiment. The company is experiencing strong leadership transitions, maintaining a robust financial ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results